Rti Biologics (RTIX) 3.74 $RTIX
RTI Surgical(R) Schedules 2014 First Quarter Earnings Conference Call for April 24, 2014
Business Wire - Thu Apr 17, 8:00AM CDT
RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a global surgical implant company, announced today that it plans to release financial results from the first quarter 2014 on Thursday, April 24, 2014, prior to the market open.
Orthobiologics Market Report 2013-2019: Allografts, Viscosupplements, DBM, BMP, Stem Cell and Others
M2 - Tue Mar 18, 11:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z3l28c/orthobiologics) has announced the addition of the "Orthobiologics Market Report 2013-2019: Allografts, Viscosupplements, DBM, BMP, Stem Cell and Others" report to their offering. The global orthobiologics market was valued at USD 3,754.6 million in 2012 and is expected to grow at a CAGR of 5.9% from 2013 to 2019 to reach at an estimated value of USD 5,519.9 million in 2019. This research report on orthobiologics provides detailed analysis of the global market and helps in understanding the driving forces responsible for the growth of this market. The report discusses the market of orthobiologics on the basis of different orthobiologic products and applications. The product segment comprises allografts, demineralized bone matrix (DBM), bone morphogenetic proteins (BMPs), viscosupplementation, synthetic bone graft substitutes, stem cell based products and machined bone. The application segment is classified into spinal fusion, trauma and reconstructive surgeries. Orthobiology is a branch of science that develops bone and tissue replacement materials for skeletal and tissue healing. Orthobiologics has been gaining popularity since it provides accelerated healing, faster recovery and reduction in number of hospital visits. A rise in the incidence of arthritis and geriatric population has triggered the growth of this market. Moreover, an increase in the obesity rate coupled with rise in demand for minimally invasive procedures has created a considerable demand for bone graft substitutes. In addition, technological advancements, growing patient awareness, rising incidences of road accidents and rising participation in sports related activities has considerably augmented the growth of this market. Market size estimates and forecasts for the period 2011 to 2019 have been provided for each of the segments, in terms of USD million, using 2012 as the base year. The CAGR (%) of each market segment for the forecast period 2013 to 2019 has been provided along with market size estimations. Scope of the Report Products - Allografts - Machined Bones - Demineralized Bone Matrix (DBM) - Bone Morphogenetic Proteins (BMPs) - Viscosupplementation - Stem Cell Therapy - Synthetic Bone Substitutes Applications - Spinal Fusion - Trauma - Reconstructive Surgery Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Orthobiologics Market, by Product Chapter 5 Global Orthobiologics Market, by Application Chapter 6 Global Orthobiologics Market, by Geography Chapter 7 Global Orthobiologics Market Share Analysis Chapter 8 Recommendations Chapter 9 Company Profiles - Alphatec Spine, Inc. - Bacterin International, Inc. - Biomet, Inc. - DePuy Synthes, Inc. (A Johnson & Johnson Company) - Exactech, Inc. - Globus Medical, Inc. - Integra LifeSciences Corporation - Medtronic, Inc. - NuVasive, Inc. - Orthofix Holdings, Inc. - Regeneration Technologies, Inc. - Sanofi - Stryker Corporation - Wright Medical Technology, Inc. - Zimmer Holdings, Inc. For more information visit http://www.researchandmarkets.com/research/z3...obiologics
2014 Bone Grafts Global Strategic Business Report - Growing Clinical Use of Bone Graft Substitutes in Surgical Procedures
M2 - Thu Mar 13, 4:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dtgc4c/bone_grafts) has announced the addition of the "Bone Grafts - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Bone Grafts in US$ Million. The US market for Bone Graft Substitutes is also analyzed by the following segments: Standard Allografts, Machined Bone Allografts, Demineralized Bone Matrix (DBM), Bone Morphogenetic Protein (BMP), Stem Cell Based Bone Grafts, and Synthetic Bone Grafts. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. MARKET DYNAMICS 3. PRODUCT OVERVIEW 4. REGULATORY ENVIRONMENT & REIMBURSEMENTS 5. PRODUCT INNOVATIONS/INTRODUCTIONS - AlloSource Introduces AlloMend - Orthofix Launches Trinity? ELITE - Synergy Biomedical to Introduce Biosphere Putty - K2M Launches VENADO Bone Graft Systems - Bonesupport Receives CE Mark Approval for Cerament|G resorbable - PlusLife? Launches Innovative Allogeneic Bone Gel for Orthopedic Uses (Australia) - RTI Surgical Introduces BioReady DBM Putty - K2M Rolls Out VESUVIUS Osteobiologic Systems - BioHorizons Introduces MinerOss? Cancellous - Amedica Introduces Dynamic Bone - Orthogen Introduces NanoGen - SIRAKOSS Introduces MaxSi - BioMimetic to Introduce Augmatrix Biocomposite Bone Graft Line - Orthofix International Introduces Collage Osteoconductive Scaffold - BioMimetic Obtains Approval from TGA for Commercialization of Augment? Bone Graft - Medtronic Launches ARTISAN Space Maintenance System - NovaBone Introduces MacroPor-Si - RTI Surgical Announces First Application of map3TM Cellular Allogeneic Bone Graft in Ankle and Foot Fusion Procedures ( US) - Integra Receives FDA Clearance for Accell Evo3 - RTI Surgical Introduces BioAdapt DBM Foam - Integra Unveils Trel-Xpress Demineralized Bone Matrix - Keystone Dental Introduces DynaMatrix Plus - Wright Introduces FUSIONFLEX Demineralized Moldable Scaffold - Micromedics Launches OsteoXpress 15cc Bone Graft Delivery Device - Bacterin Unveils OsteoSponge?SC - Integra Launches Allograft Cancellous Sponge - Orthos Receives CE Approval for ?Gel Synthetic Bone Graft Substitute 6. RECENT INDUSTRY ACTIVITY - RTI Biologics Acquires Pioneer Surgical Technology - Wright Medical Group Acquires BioMimetic Therapeutics - Titan Spine Enters into Distribution Agreement with Biomet - Bioventus and Pfizer Enter into Agreement - AlloSource Enters into Partnership with Humacyte - MicroPort Medical to Acquire OrthoRecon Business of Wright Medical Group - J&J Takes Over Synthes - Stryker Acquires Orthovita - Zimmer Dental and Curasan Enter into Distribution Agreement - Cayenne Medical Enters into Partnership with Parametrics Medical - NuVasive Signs Licensing Agreement with AlloSource - Stryker Divests OP-1 Product Range 7. FOCUS ON SELECT PLAYERS 8. MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. EUROPE 3. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles 61 companies including many key and niche players such as: - AlloSource - Biomet - DePuy Synthes - Synthes - DePuy Spine - Exactech - Integra LifeSciences - LifeNet Health - Medtronic - NovaBone Products - NuVasive, - Olympus Biotech - RTI Surgical - Smith & Nephew - Stryker - Wright Medical Technology - BioMimetic Therapeutics - Zimmer For more information visit http://www.researchandmarkets.com/research/dt...one_grafts About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Why RTI Surgical, Inc. Shares Temporarily Spiked Higher
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 12, 12:54PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of RTI Surgical , a producer of orthopedic...
Traders Get Bullish on Shares of RTI Biologics, Shares Up 7.1% (RTIX)
Comtex SmarTrend(R) - Wed Mar 12, 10:12AM CDT
RTI Biologics (NASDAQ:RTIX) is one of today's best performing low-priced stocks, up 7.1% to $4.23 on 1.6x average daily volume. Thus far today, RTI Biologics has traded 409,000 shares, vs. average volume of 262,000 shares per day. The stock has outperformed the Dow (7.1% to the Dow's -0.2%) and outperformed the S&P 500 (7.1% to the S&P's -0.2%) during today's trading.
RTI Surgical(TM) Launches Two Natural Bone Grafting Solutions at AAOS Annual Meeting
Business Wire - Wed Mar 12, 7:00AM CDT
RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a leading global surgical implant company, is launching two new biological solutions at the American Academy of Orthopaedic Surgeons (AAOS) annual meeting in New Orleans this week. NanOss(R) Bioactive 3D, a synthetic three dimensional bioscaffold which supports bone formation, and map3(TM) Cellular Allogeneic Bone Graft, an implant that contains the three essential elements needed to generate and maintain new bone, will be introduced at the RTI Surgical exhibit at booth 5937 (Hall H) during the AAOS meeting.
Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016
M2 - Wed Mar 12, 6:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lq46f/regenerative) has announced the addition of the "Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016" report to their offering. There is a high demand for synthetic organ transplants in the market. Regenerative medicine helps in the development of artificial organs. The introduction of artificial organs for implantation is expected to encourage many vendors and research organizations to develop advanced stem cell products, therapies, and regenerative products. It will also help reduce the long organ waiting list. For instance, custom-made windpipe can be made using regenerative products within a week. The first ever implant of a synthetic trachea took place in June 2011. The synthetic trachea was made from minuscule plastic fibers and was covered in stem cells taken from a human bone marrow. Surgeons successfully implanted this synthetic trachea into a 36-year-old patient with late-stage tracheal cancer at Karolinska University Hospital in Stockholm. Thus, the use of synthetic organs in transplant surgeries is expected to have a positive impact on the growth of the market. According to the report, one of the main drivers of this market is the increasing prevalence of degenerative diseases. Regenerative products have helped in addressing the unmet needs of various disease areas. Another major driver of the market is the significant advances seen in R&D. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Vendor Landscape 8. Buying Criteria 9. Market Growth Drivers 10. Drivers and their Impact 11. Market Challenges 12. Impact of Drivers and Challenges 13. Market Trends 14. Key Vendor Analysis 15. Other Reports in this Series Companies Mentioned: - Advanced Cell Technology Inc. - Arteriocyte Inc. - Athersys Inc. - Baxter International Inc. - CryoLife - Cytori Therapeutics Inc. - Genzyme Corp. - Geron Corp. - InVivo Therapeutics - Inc. - Integra Life Sciences Holdings Corp. - Kensey Nash Corp. - Kinetic Concepts Inc. - Medtronic Inc. - NeoStem Inc. - Osiris Therapeutics Inc. - Osteotech Inc. - RTI Biologics Inc. - Stryker Corp. - Zimmer Holdings Inc. For more information visit http://www.researchandmarkets.com/research/4l...generative
RTI Surgical(TM) Receives CE Mark Approval for Fortiva(TM) Porcine Dermis
Business Wire - Tue Mar 11, 4:00PM CDT
RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a leading global surgical implant company, announced today that the company received approval to CE mark Fortiva(TM) Porcine Dermis and will begin distribution throughout Europe. Fortiva received 510(k) clearance from the U.S. Food and Drug and Administration (FDA) in March 2013 and was launched in the U.S. in July 2013. The implant is manufactured at RTI's Neunkirchen, Germany facility.
6th Annual India Roads Conference 2014 Out Now for Analysis
M2 - Wed Feb 26, 6:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/z7m627/6th_annual_india) has announced the addition of the "6th Annual India Roads Conference 2014." conference to their offering. When? 26th March, 2014 Where? ITC Sherton, Saket - New Delhi With a clear intent to boost the India's road sector, This conference has been meticulously programmed to encompass the challenges and opportunities of the road sector in India for the past five editions. This conference has a view to discuss the issues relating to policy & regulatory framework, clearances, dispute resolution, time bound execution of PPP projects, technological advancement, project time & cost overruns, skilled resource shortage, finance and funding issues and other key areas. As the theme "Accelerating India's Road to Growth" suggests, the conference aims to deliberate upon the procedural constraints adversely impacting the ability to implement road projects in India. As always we are creating this platform as a congregation of the stakeholders and industry captains to engage in solution oriented discussions and put forward suitable measures to accelerate the pace of road development through interactive sessions. 6th India Roads Conference strives to: - Enhance the policy and regulatory framework for the road sector - Focus on the factors leading to project time and cost overruns of major road projects - Discuss the underlying issues like dispute resolution, Project funding and finance etc. - Provide a platform to elicit the views & suggestions of the industry for Accelerating India's Road to Growth. Speakers - Amit Vora, Financial Expert, CRISIL - AK Lakhotia, Chairman, MBL Infra - Arther Shahab, CEO, Uniquest Infra - Avadesh Singh, CEO, EGIS - Col Surinder Kuda, Executive Director, Ashoka Buildcon - Deepak Mittal, CEO, KMCIL - Harish Mathur, Chief Executive, ITNL - Hemant Modi, CEO, JMC, Projects - Hemant Kanoria, CMD, SREI Infra - Palash Srivastava, Director PPP & Programs, IDFC - Raj Kalady, MD, PMI - Rohit Inamdar, Sr VP, ICRA - SL Verma, Sr VP, Lanco Infratech - Vikas Sharma, CEO, Supreme Infra For more information visit http://www.researchandmarkets.com/research/z7...nual_india About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
RTI Surgical(TM) Announces Launch of Two New Spine Systems:Aspect (R) Anterior Cervical Plate System and MaxFuse(TM) VBR System
Business Wire - Mon Feb 24, 8:45AM CST
RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a leading global surgical implant company, announced today the full market launch of the MaxFuse(TM) Vertebral Body Replacement System and the Aspect(R) Anterior Cervical Plate System. Both systems are designed for use in spine fusion and are currently available for U.S. distribution.
RTI Surgical sees solid activity on earnings estimate revision front - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 7:39AM CST
RTI Surgical could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision front
RTI Surgical(R) Announces Renewal of Supply and Distribution Agreement with Zimmer, Inc. for Its Trauma Business
Business Wire - Wed Feb 19, 8:00AM CST
RTI Surgical Inc. (RTI) (Nasdaq:RTIX), a global surgical implant company, announced today that the company's wholly owned subsidiary, Pioneer Surgical Technology Inc. DBA RTI Surgical, has signed an agreement with Zimmer, Inc. (NYSE:ZMH) (SWX:ZMH) to supply integrated plates and cables, cannulated screws and instrumentation for Zimmer's trauma business.
RTI Surgical (RTIX) is Overbought, What's Next? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 7:35AM CST
RTI Surgical (RTIX) is Overbought, What’s Next?
RTI Surgical(TM) Announces 2013 Fourth Quarter, Full Year Results, 2014 Financial Guidance
Business Wire - Thu Feb 13, 7:00AM CST
RTI Surgical Inc. (RTI) (Nasdaq:RTIX), a global surgical implant company, reported operating results for the fourth quarter and full year of 2013 as follows:
RTI Surgical Schedules 2013 Fourth Quarter, Year End Earnings and Conference Call for February 13, 2014
Business Wire - Thu Feb 06, 8:20AM CST
RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a global surgical implant company, announced today that it plans to release financial results from the fourth quarter and year end 2013 on Thursday, Feb. 13, 2014, prior to the market open.
Global Biomaterials Market 2012-2016: High R&D Costs Could Pose a Challenge to the Growth of the Market
M2 - Wed Feb 05, 10:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/kl58bq/global) has announced the addition of the "Global Biomaterials Market 2012-2016" report to their offering. The analysts forecast the Global Biomaterials market to grow at a CAGR of 14.85 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing aging population. The Global Biomaterials market has also been witnessing the emergence of innovative biomaterial products. However, high R&D costs could pose a challenge to the growth of this market. The key vendors dominating this space include Biomet Inc., Evonik Industries AG, Exactech Inc., and Wright Medical Group Inc. The other vendors mentioned in this report are 3DM Inc., AdvanSource Biomaterials Corp., Allergan Inc., Alphatec Spine Inc., Amedica Corp., Angiotech Pharmaceuticals Inc., Basf SE, Bayer AG, Berkeley Advanced Biomaterials Inc., Biocomposites Ltd., BioSyntech Inc., Cam Bioceramics BV, Carpenter Technology Corp., Ceradyne Inc., Ceramtec Collagen Matrix Inc., CollPlant Holdings Ltd., Covalon Technologies Ltd., CryoLife Inc., Dentsply International Inc., Depuy Orthopaedics Inc., Dsm Biomedical Inc., ETEX Corp., Heraeus Medical Components Inc., Hycail Finland OY, Integra LifeSciences Holdings Corp., Invibio Ltd., Kyocera Corp., Landec Corp., Materion Corp., Medtronic Inc., Morgan Technical Ceramics, Orthovita Inc., Osteotech Inc., Purac Biomaterials, RTI Biologics Inc., Sigma-Aldrich Corp., Starch Medical Inc., Stryker Corp., Ticona GmbH, Ulbrich Stainless Steels & Special Metals Inc., and Zimmer Holdings Inc. Commenting on the report, an analyst from the team said: There has been steady innovation in the Global Biomaterials market with several players increasing R&D expenditure every year. For instance, the use of carbon fiber in conjunction with biomaterials for the manufacture of composite materials is being explored. While innovation is imperative in an industry such as this where competition is rampant, the need for novel solutions to cater to patient needs in the Medical industry is also expected to lead to innovation in the market. Biomaterials were traditionally used for repair and replacement of body tissues. However, there has been an increasing focus on the provision of biomaterials for self-healing in patients. Thus, the Global Biomaterials market is expected to witness innovation. For more information visit http://www.researchandmarkets.com/research/kl58bq/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
4 Health Care Stocks Under $10 to Watch
at The Street - Fri Jan 24, 6:00AM CST
Keep these under-$10 health care stocks on your radar.
RTI Surgical(TM) Announces Agreement to Supply Complete Surgical Specialties Portfolio to Yankee Alliance Members
Business Wire - Mon Jan 13, 8:03AM CST
RTI Surgical Inc. (RTI) (Nasdaq:RTIX), a leading global surgical implant company, announced a new agreement with Yankee Alliance, a group purchasing organization with more than 14,700 members. The agreement covers RTI's complete line of surgical specialties implants and is effective starting Jan. 1, 2014 for a term of three years.
Orthobiologics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Fri Jan 03, 3:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/3z6jpm/orthobiologics) has announced the addition of the "Orthobiologics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Orthobiology is a branch of science that develops bone and tissue replacement materials for fast healing and quick recovery of injured muscles, broken bones, ligaments and tendons. Orthobiologics is considered as a highly lucrative market owing to significant growth opportunities. One of the major driver for the growth of this industry is certain limitations that are associated with autografts and allografts. The rise in number of spinal fusion surgeries has created the demand for bone graft substitutes and has consequently boosted the overall growth of this industry. In addition, rise in the incidence of arthritis, increase in geriatric population and increase in obesity rate has triggered the growth of this market. Technological advancements, growing demand for minimally invasive procedures and rising patient awareness are the other factors that has considerably augmented the growth of this market. The global orthobiologics market was valued at USD 3,754.6 million in 2012 and is expected to grow at a CAGR of 5.9%from 2013 to 2019 to reach at an estimated value of USD 5,519.9 million in 2019. At present, viscosupplementation accounts for the largest share of the orthobiologics market. The growth in this market is attributed to growing popularity of knee treatments and its ability to act as an effective pain killer as compared to NSAIDS and others. This market is followed by bone morphogenetic proteins (BMPs) which is characterized by its ability to provide faster recovery, lesser pain and ability to stimulate patients own cells for regeneration. However, the market is expected to show a negative growth rate during the forecast period due to decline in the sales of 'INFUSE' a Medtronic product. Severe side effects associated with INFUSE due to its heavy off label usage led to recall of this product by the U.S FDA. Synthetic bone substitutes and stem cell based products are expected to witness a significant growth during the forecast period. The growth of these segments is witnessed due to reduced cost, quick recovery and eliminated risk of disease transmission. Key Topics Covered - Preface - Executive Summary - Market Overview - Global Orthobiologics Market, by Product - Global Orthobiologics Market, by Application - Global Orthobiologics Market, by Geography - Global Orthobiologics Market Share Analysis - Recommendations - Company Profiles Companies Mentioned - Alphatec Spine - Bacterin International - Biomet - DePuy Synthes (A Johnson & Johnson Company) - Exactech. - Globus Medical - Integra LifeSciences Corporation - Medtronic - NuVasive - Orthofix Holdings - Regeneration Technologies - Sanofi - Stryker Corporation - Wright Medical Technology - Zimmer Holdings For more information visit http://www.researchandmarkets.com/research/3z...obiologics About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
State-of-the-Art Tissue Engineering and Organ Regeneration Technologies Yield Healthcare Market Disruption
PR Newswire Europe - Thu Dec 19, 2:35AM CST
-- Frost & Sullivan: An increasing number of revolutionary applications emerge, conceivably overcoming global organ shortage
RTI Surgical(R) Schedules 2014 First Quarter Earnings Conference Call for April 24, 2014
Business Wire - Thu Apr 17, 8:00AM CDT
RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a global surgical implant company, announced today that it plans to release financial results from the first quarter 2014 on Thursday, April 24, 2014, prior to the market open.
Orthobiologics Market Report 2013-2019: Allografts, Viscosupplements, DBM, BMP, Stem Cell and Others
M2 - Tue Mar 18, 11:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z3l28c/orthobiologics) has announced the addition of the "Orthobiologics Market Report 2013-2019: Allografts, Viscosupplements, DBM, BMP, Stem Cell and Others" report to their offering. The global orthobiologics market was valued at USD 3,754.6 million in 2012 and is expected to grow at a CAGR of 5.9% from 2013 to 2019 to reach at an estimated value of USD 5,519.9 million in 2019. This research report on orthobiologics provides detailed analysis of the global market and helps in understanding the driving forces responsible for the growth of this market. The report discusses the market of orthobiologics on the basis of different orthobiologic products and applications. The product segment comprises allografts, demineralized bone matrix (DBM), bone morphogenetic proteins (BMPs), viscosupplementation, synthetic bone graft substitutes, stem cell based products and machined bone. The application segment is classified into spinal fusion, trauma and reconstructive surgeries. Orthobiology is a branch of science that develops bone and tissue replacement materials for skeletal and tissue healing. Orthobiologics has been gaining popularity since it provides accelerated healing, faster recovery and reduction in number of hospital visits. A rise in the incidence of arthritis and geriatric population has triggered the growth of this market. Moreover, an increase in the obesity rate coupled with rise in demand for minimally invasive procedures has created a considerable demand for bone graft substitutes. In addition, technological advancements, growing patient awareness, rising incidences of road accidents and rising participation in sports related activities has considerably augmented the growth of this market. Market size estimates and forecasts for the period 2011 to 2019 have been provided for each of the segments, in terms of USD million, using 2012 as the base year. The CAGR (%) of each market segment for the forecast period 2013 to 2019 has been provided along with market size estimations. Scope of the Report Products - Allografts - Machined Bones - Demineralized Bone Matrix (DBM) - Bone Morphogenetic Proteins (BMPs) - Viscosupplementation - Stem Cell Therapy - Synthetic Bone Substitutes Applications - Spinal Fusion - Trauma - Reconstructive Surgery Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Orthobiologics Market, by Product Chapter 5 Global Orthobiologics Market, by Application Chapter 6 Global Orthobiologics Market, by Geography Chapter 7 Global Orthobiologics Market Share Analysis Chapter 8 Recommendations Chapter 9 Company Profiles - Alphatec Spine, Inc. - Bacterin International, Inc. - Biomet, Inc. - DePuy Synthes, Inc. (A Johnson & Johnson Company) - Exactech, Inc. - Globus Medical, Inc. - Integra LifeSciences Corporation - Medtronic, Inc. - NuVasive, Inc. - Orthofix Holdings, Inc. - Regeneration Technologies, Inc. - Sanofi - Stryker Corporation - Wright Medical Technology, Inc. - Zimmer Holdings, Inc. For more information visit http://www.researchandmarkets.com/research/z3...obiologics
2014 Bone Grafts Global Strategic Business Report - Growing Clinical Use of Bone Graft Substitutes in Surgical Procedures
M2 - Thu Mar 13, 4:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dtgc4c/bone_grafts) has announced the addition of the "Bone Grafts - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Bone Grafts in US$ Million. The US market for Bone Graft Substitutes is also analyzed by the following segments: Standard Allografts, Machined Bone Allografts, Demineralized Bone Matrix (DBM), Bone Morphogenetic Protein (BMP), Stem Cell Based Bone Grafts, and Synthetic Bone Grafts. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. MARKET DYNAMICS 3. PRODUCT OVERVIEW 4. REGULATORY ENVIRONMENT & REIMBURSEMENTS 5. PRODUCT INNOVATIONS/INTRODUCTIONS - AlloSource Introduces AlloMend - Orthofix Launches Trinity? ELITE - Synergy Biomedical to Introduce Biosphere Putty - K2M Launches VENADO Bone Graft Systems - Bonesupport Receives CE Mark Approval for Cerament|G resorbable - PlusLife? Launches Innovative Allogeneic Bone Gel for Orthopedic Uses (Australia) - RTI Surgical Introduces BioReady DBM Putty - K2M Rolls Out VESUVIUS Osteobiologic Systems - BioHorizons Introduces MinerOss? Cancellous - Amedica Introduces Dynamic Bone - Orthogen Introduces NanoGen - SIRAKOSS Introduces MaxSi - BioMimetic to Introduce Augmatrix Biocomposite Bone Graft Line - Orthofix International Introduces Collage Osteoconductive Scaffold - BioMimetic Obtains Approval from TGA for Commercialization of Augment? Bone Graft - Medtronic Launches ARTISAN Space Maintenance System - NovaBone Introduces MacroPor-Si - RTI Surgical Announces First Application of map3TM Cellular Allogeneic Bone Graft in Ankle and Foot Fusion Procedures ( US) - Integra Receives FDA Clearance for Accell Evo3 - RTI Surgical Introduces BioAdapt DBM Foam - Integra Unveils Trel-Xpress Demineralized Bone Matrix - Keystone Dental Introduces DynaMatrix Plus - Wright Introduces FUSIONFLEX Demineralized Moldable Scaffold - Micromedics Launches OsteoXpress 15cc Bone Graft Delivery Device - Bacterin Unveils OsteoSponge?SC - Integra Launches Allograft Cancellous Sponge - Orthos Receives CE Approval for ?Gel Synthetic Bone Graft Substitute 6. RECENT INDUSTRY ACTIVITY - RTI Biologics Acquires Pioneer Surgical Technology - Wright Medical Group Acquires BioMimetic Therapeutics - Titan Spine Enters into Distribution Agreement with Biomet - Bioventus and Pfizer Enter into Agreement - AlloSource Enters into Partnership with Humacyte - MicroPort Medical to Acquire OrthoRecon Business of Wright Medical Group - J&J Takes Over Synthes - Stryker Acquires Orthovita - Zimmer Dental and Curasan Enter into Distribution Agreement - Cayenne Medical Enters into Partnership with Parametrics Medical - NuVasive Signs Licensing Agreement with AlloSource - Stryker Divests OP-1 Product Range 7. FOCUS ON SELECT PLAYERS 8. MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. EUROPE 3. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles 61 companies including many key and niche players such as: - AlloSource - Biomet - DePuy Synthes - Synthes - DePuy Spine - Exactech - Integra LifeSciences - LifeNet Health - Medtronic - NovaBone Products - NuVasive, - Olympus Biotech - RTI Surgical - Smith & Nephew - Stryker - Wright Medical Technology - BioMimetic Therapeutics - Zimmer For more information visit http://www.researchandmarkets.com/research/dt...one_grafts About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Why RTI Surgical, Inc. Shares Temporarily Spiked Higher
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 12, 12:54PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of RTI Surgical , a producer of orthopedic...
Traders Get Bullish on Shares of RTI Biologics, Shares Up 7.1% (RTIX)
Comtex SmarTrend(R) - Wed Mar 12, 10:12AM CDT
RTI Biologics (NASDAQ:RTIX) is one of today's best performing low-priced stocks, up 7.1% to $4.23 on 1.6x average daily volume. Thus far today, RTI Biologics has traded 409,000 shares, vs. average volume of 262,000 shares per day. The stock has outperformed the Dow (7.1% to the Dow's -0.2%) and outperformed the S&P 500 (7.1% to the S&P's -0.2%) during today's trading.
RTI Surgical(TM) Launches Two Natural Bone Grafting Solutions at AAOS Annual Meeting
Business Wire - Wed Mar 12, 7:00AM CDT
RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a leading global surgical implant company, is launching two new biological solutions at the American Academy of Orthopaedic Surgeons (AAOS) annual meeting in New Orleans this week. NanOss(R) Bioactive 3D, a synthetic three dimensional bioscaffold which supports bone formation, and map3(TM) Cellular Allogeneic Bone Graft, an implant that contains the three essential elements needed to generate and maintain new bone, will be introduced at the RTI Surgical exhibit at booth 5937 (Hall H) during the AAOS meeting.
Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016
M2 - Wed Mar 12, 6:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lq46f/regenerative) has announced the addition of the "Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016" report to their offering. There is a high demand for synthetic organ transplants in the market. Regenerative medicine helps in the development of artificial organs. The introduction of artificial organs for implantation is expected to encourage many vendors and research organizations to develop advanced stem cell products, therapies, and regenerative products. It will also help reduce the long organ waiting list. For instance, custom-made windpipe can be made using regenerative products within a week. The first ever implant of a synthetic trachea took place in June 2011. The synthetic trachea was made from minuscule plastic fibers and was covered in stem cells taken from a human bone marrow. Surgeons successfully implanted this synthetic trachea into a 36-year-old patient with late-stage tracheal cancer at Karolinska University Hospital in Stockholm. Thus, the use of synthetic organs in transplant surgeries is expected to have a positive impact on the growth of the market. According to the report, one of the main drivers of this market is the increasing prevalence of degenerative diseases. Regenerative products have helped in addressing the unmet needs of various disease areas. Another major driver of the market is the significant advances seen in R&D. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Vendor Landscape 8. Buying Criteria 9. Market Growth Drivers 10. Drivers and their Impact 11. Market Challenges 12. Impact of Drivers and Challenges 13. Market Trends 14. Key Vendor Analysis 15. Other Reports in this Series Companies Mentioned: - Advanced Cell Technology Inc. - Arteriocyte Inc. - Athersys Inc. - Baxter International Inc. - CryoLife - Cytori Therapeutics Inc. - Genzyme Corp. - Geron Corp. - InVivo Therapeutics - Inc. - Integra Life Sciences Holdings Corp. - Kensey Nash Corp. - Kinetic Concepts Inc. - Medtronic Inc. - NeoStem Inc. - Osiris Therapeutics Inc. - Osteotech Inc. - RTI Biologics Inc. - Stryker Corp. - Zimmer Holdings Inc. For more information visit http://www.researchandmarkets.com/research/4l...generative
RTI Surgical(TM) Receives CE Mark Approval for Fortiva(TM) Porcine Dermis
Business Wire - Tue Mar 11, 4:00PM CDT
RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a leading global surgical implant company, announced today that the company received approval to CE mark Fortiva(TM) Porcine Dermis and will begin distribution throughout Europe. Fortiva received 510(k) clearance from the U.S. Food and Drug and Administration (FDA) in March 2013 and was launched in the U.S. in July 2013. The implant is manufactured at RTI's Neunkirchen, Germany facility.
6th Annual India Roads Conference 2014 Out Now for Analysis
M2 - Wed Feb 26, 6:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/z7m627/6th_annual_india) has announced the addition of the "6th Annual India Roads Conference 2014." conference to their offering. When? 26th March, 2014 Where? ITC Sherton, Saket - New Delhi With a clear intent to boost the India's road sector, This conference has been meticulously programmed to encompass the challenges and opportunities of the road sector in India for the past five editions. This conference has a view to discuss the issues relating to policy & regulatory framework, clearances, dispute resolution, time bound execution of PPP projects, technological advancement, project time & cost overruns, skilled resource shortage, finance and funding issues and other key areas. As the theme "Accelerating India's Road to Growth" suggests, the conference aims to deliberate upon the procedural constraints adversely impacting the ability to implement road projects in India. As always we are creating this platform as a congregation of the stakeholders and industry captains to engage in solution oriented discussions and put forward suitable measures to accelerate the pace of road development through interactive sessions. 6th India Roads Conference strives to: - Enhance the policy and regulatory framework for the road sector - Focus on the factors leading to project time and cost overruns of major road projects - Discuss the underlying issues like dispute resolution, Project funding and finance etc. - Provide a platform to elicit the views & suggestions of the industry for Accelerating India's Road to Growth. Speakers - Amit Vora, Financial Expert, CRISIL - AK Lakhotia, Chairman, MBL Infra - Arther Shahab, CEO, Uniquest Infra - Avadesh Singh, CEO, EGIS - Col Surinder Kuda, Executive Director, Ashoka Buildcon - Deepak Mittal, CEO, KMCIL - Harish Mathur, Chief Executive, ITNL - Hemant Modi, CEO, JMC, Projects - Hemant Kanoria, CMD, SREI Infra - Palash Srivastava, Director PPP & Programs, IDFC - Raj Kalady, MD, PMI - Rohit Inamdar, Sr VP, ICRA - SL Verma, Sr VP, Lanco Infratech - Vikas Sharma, CEO, Supreme Infra For more information visit http://www.researchandmarkets.com/research/z7...nual_india About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
RTI Surgical(TM) Announces Launch of Two New Spine Systems:Aspect (R) Anterior Cervical Plate System and MaxFuse(TM) VBR System
Business Wire - Mon Feb 24, 8:45AM CST
RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a leading global surgical implant company, announced today the full market launch of the MaxFuse(TM) Vertebral Body Replacement System and the Aspect(R) Anterior Cervical Plate System. Both systems are designed for use in spine fusion and are currently available for U.S. distribution.
RTI Surgical sees solid activity on earnings estimate revision front - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 7:39AM CST
RTI Surgical could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision front
RTI Surgical(R) Announces Renewal of Supply and Distribution Agreement with Zimmer, Inc. for Its Trauma Business
Business Wire - Wed Feb 19, 8:00AM CST
RTI Surgical Inc. (RTI) (Nasdaq:RTIX), a global surgical implant company, announced today that the company's wholly owned subsidiary, Pioneer Surgical Technology Inc. DBA RTI Surgical, has signed an agreement with Zimmer, Inc. (NYSE:ZMH) (SWX:ZMH) to supply integrated plates and cables, cannulated screws and instrumentation for Zimmer's trauma business.
RTI Surgical (RTIX) is Overbought, What's Next? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 7:35AM CST
RTI Surgical (RTIX) is Overbought, What’s Next?
RTI Surgical(TM) Announces 2013 Fourth Quarter, Full Year Results, 2014 Financial Guidance
Business Wire - Thu Feb 13, 7:00AM CST
RTI Surgical Inc. (RTI) (Nasdaq:RTIX), a global surgical implant company, reported operating results for the fourth quarter and full year of 2013 as follows:
RTI Surgical Schedules 2013 Fourth Quarter, Year End Earnings and Conference Call for February 13, 2014
Business Wire - Thu Feb 06, 8:20AM CST
RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a global surgical implant company, announced today that it plans to release financial results from the fourth quarter and year end 2013 on Thursday, Feb. 13, 2014, prior to the market open.
Global Biomaterials Market 2012-2016: High R&D Costs Could Pose a Challenge to the Growth of the Market
M2 - Wed Feb 05, 10:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/kl58bq/global) has announced the addition of the "Global Biomaterials Market 2012-2016" report to their offering. The analysts forecast the Global Biomaterials market to grow at a CAGR of 14.85 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing aging population. The Global Biomaterials market has also been witnessing the emergence of innovative biomaterial products. However, high R&D costs could pose a challenge to the growth of this market. The key vendors dominating this space include Biomet Inc., Evonik Industries AG, Exactech Inc., and Wright Medical Group Inc. The other vendors mentioned in this report are 3DM Inc., AdvanSource Biomaterials Corp., Allergan Inc., Alphatec Spine Inc., Amedica Corp., Angiotech Pharmaceuticals Inc., Basf SE, Bayer AG, Berkeley Advanced Biomaterials Inc., Biocomposites Ltd., BioSyntech Inc., Cam Bioceramics BV, Carpenter Technology Corp., Ceradyne Inc., Ceramtec Collagen Matrix Inc., CollPlant Holdings Ltd., Covalon Technologies Ltd., CryoLife Inc., Dentsply International Inc., Depuy Orthopaedics Inc., Dsm Biomedical Inc., ETEX Corp., Heraeus Medical Components Inc., Hycail Finland OY, Integra LifeSciences Holdings Corp., Invibio Ltd., Kyocera Corp., Landec Corp., Materion Corp., Medtronic Inc., Morgan Technical Ceramics, Orthovita Inc., Osteotech Inc., Purac Biomaterials, RTI Biologics Inc., Sigma-Aldrich Corp., Starch Medical Inc., Stryker Corp., Ticona GmbH, Ulbrich Stainless Steels & Special Metals Inc., and Zimmer Holdings Inc. Commenting on the report, an analyst from the team said: There has been steady innovation in the Global Biomaterials market with several players increasing R&D expenditure every year. For instance, the use of carbon fiber in conjunction with biomaterials for the manufacture of composite materials is being explored. While innovation is imperative in an industry such as this where competition is rampant, the need for novel solutions to cater to patient needs in the Medical industry is also expected to lead to innovation in the market. Biomaterials were traditionally used for repair and replacement of body tissues. However, there has been an increasing focus on the provision of biomaterials for self-healing in patients. Thus, the Global Biomaterials market is expected to witness innovation. For more information visit http://www.researchandmarkets.com/research/kl58bq/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
4 Health Care Stocks Under $10 to Watch
at The Street - Fri Jan 24, 6:00AM CST
Keep these under-$10 health care stocks on your radar.
RTI Surgical(TM) Announces Agreement to Supply Complete Surgical Specialties Portfolio to Yankee Alliance Members
Business Wire - Mon Jan 13, 8:03AM CST
RTI Surgical Inc. (RTI) (Nasdaq:RTIX), a leading global surgical implant company, announced a new agreement with Yankee Alliance, a group purchasing organization with more than 14,700 members. The agreement covers RTI's complete line of surgical specialties implants and is effective starting Jan. 1, 2014 for a term of three years.
Orthobiologics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Fri Jan 03, 3:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/3z6jpm/orthobiologics) has announced the addition of the "Orthobiologics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Orthobiology is a branch of science that develops bone and tissue replacement materials for fast healing and quick recovery of injured muscles, broken bones, ligaments and tendons. Orthobiologics is considered as a highly lucrative market owing to significant growth opportunities. One of the major driver for the growth of this industry is certain limitations that are associated with autografts and allografts. The rise in number of spinal fusion surgeries has created the demand for bone graft substitutes and has consequently boosted the overall growth of this industry. In addition, rise in the incidence of arthritis, increase in geriatric population and increase in obesity rate has triggered the growth of this market. Technological advancements, growing demand for minimally invasive procedures and rising patient awareness are the other factors that has considerably augmented the growth of this market. The global orthobiologics market was valued at USD 3,754.6 million in 2012 and is expected to grow at a CAGR of 5.9%from 2013 to 2019 to reach at an estimated value of USD 5,519.9 million in 2019. At present, viscosupplementation accounts for the largest share of the orthobiologics market. The growth in this market is attributed to growing popularity of knee treatments and its ability to act as an effective pain killer as compared to NSAIDS and others. This market is followed by bone morphogenetic proteins (BMPs) which is characterized by its ability to provide faster recovery, lesser pain and ability to stimulate patients own cells for regeneration. However, the market is expected to show a negative growth rate during the forecast period due to decline in the sales of 'INFUSE' a Medtronic product. Severe side effects associated with INFUSE due to its heavy off label usage led to recall of this product by the U.S FDA. Synthetic bone substitutes and stem cell based products are expected to witness a significant growth during the forecast period. The growth of these segments is witnessed due to reduced cost, quick recovery and eliminated risk of disease transmission. Key Topics Covered - Preface - Executive Summary - Market Overview - Global Orthobiologics Market, by Product - Global Orthobiologics Market, by Application - Global Orthobiologics Market, by Geography - Global Orthobiologics Market Share Analysis - Recommendations - Company Profiles Companies Mentioned - Alphatec Spine - Bacterin International - Biomet - DePuy Synthes (A Johnson & Johnson Company) - Exactech. - Globus Medical - Integra LifeSciences Corporation - Medtronic - NuVasive - Orthofix Holdings - Regeneration Technologies - Sanofi - Stryker Corporation - Wright Medical Technology - Zimmer Holdings For more information visit http://www.researchandmarkets.com/research/3z...obiologics About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
State-of-the-Art Tissue Engineering and Organ Regeneration Technologies Yield Healthcare Market Disruption
PR Newswire Europe - Thu Dec 19, 2:35AM CST
-- Frost & Sullivan: An increasing number of revolutionary applications emerge, conceivably overcoming global organ shortage
